{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-10-22",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 2
    }
  },
  "results": [
    {
      "discontinued_date": "10/19/2026",
      "update_type": "New",
      "initial_posting_date": "10/19/2026",
      "package_ndc": "49702-204-13",
      "generic_name": "Lamivudine Tablet",
      "contact_info": "800-844-8872",
      "related_info": "The anticipated date that ViiV will cease distribution of the products is approximately April 15, 2027; Discontinuation of the manufacture of the drug",
      "update_date": "10/19/2026",
      "therapeutic_category": [
        "Antiviral"
      ],
      "dosage_form": "Tablet",
      "presentation": "Epivir, Tablet, 300 mg (NDC 49702-204-13)",
      "company_name": "ViiV Healthcare Company",
      "status": "To Be Discontinued"
    }
  ]
}